Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:39:35 EDT Tue 14 Apr 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:TLSA - TIZIANA LIFE SCIENCES LTD - https://www.tizianalifesciences.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TLSA - Q2.11.24·1.395.21.29+0.1412.2372.24151,1511.15  1.32  1.152.60  0.760717:22:1407:0015 min RT 2¢

Recent Trades - Last 10 of 1151
Time ETExPriceChangeVolume
17:22:14Q1.290.142
16:10:05Q1.290.141
16:10:05Q1.290.141
16:04:39Q1.290.141
16:04:28Q1.290.141
16:04:14Q1.290.141
16:02:37Q1.27180.121832
16:02:22Q1.270.1212
16:00:00Q1.290.14433
16:00:00Q1.290.1485

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-04-14 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
2026-04-01 07:00U:TLSANews ReleaseTiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
2026-02-25 07:00U:TLSANews ReleaseTiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
2026-01-20 11:15U:TLSANews ReleaseTiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
2026-01-16 14:46U:TLSANews ReleaseTiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
2026-01-16 07:00U:TLSANews ReleaseTiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
2026-01-09 07:00U:TLSANews ReleaseTiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
2025-12-29 08:00U:TLSANews ReleaseTiziana Files Annual Safety Report for Intranasal Foralumab with FDA
2025-12-19 11:01U:TLSANews ReleaseTiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
2025-12-17 10:00U:TLSANews ReleaseTiziana Life Sciences to Ring the Closing Bell at Nasdaq
2025-12-17 08:45U:TLSANews ReleaseTiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial
2025-12-15 15:08U:TLSANews ReleaseTiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
2025-12-15 07:30U:TLSANews ReleaseTiziana Life Sciences Announces Withdrawal of Proposed Public Offering
2025-12-12 14:10U:TLSANews ReleaseTiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial
2025-12-02 07:00U:TLSANews ReleaseTiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
2025-11-25 08:30U:TLSANews ReleaseTiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
2025-11-13 08:30U:TLSANews ReleaseTiziana Life Sciences to Present at Jefferies Global Healthcare Conference
2025-11-04 07:00U:TLSANews ReleaseAquestive Therapeutics Announces Leadership Expansion to Support Growth
2025-10-29 07:00U:TLSANews ReleaseTiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
2025-09-30 08:30U:TLSANews ReleaseTiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia